Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Derivatives of imidazotriazine and pyrrolotriazine C-nucleosides as potential new anti-HCV agents.

Draffan AG, Frey B, Fraser BH, Pool B, Gannon C, Tyndall EM, Cianci J, Harding M, Lilly M, Hufton R, Halim R, Jahangiri S, Bond S, Jeynes TP, Nguyen VT, Wirth V, Luttick A, Tilmanis D, Pryor M, Porter K, Morton CJ, Lin B, Duan J, Bethell RC, Kukolj G, Simoneau B, Tucker SP.

Bioorg Med Chem Lett. 2014 Nov 1;24(21):4984-8. doi: 10.1016/j.bmcl.2014.09.030. Epub 2014 Sep 21.

PMID:
25288185
2.

CD160 isoforms and regulation of CD4 and CD8 T-cell responses.

El-Far M, Pellerin C, Pilote L, Fortin JF, Lessard IA, Peretz Y, Wardrop E, Salois P, Bethell RC, Cordingley MG, Kukolj G.

J Transl Med. 2014 Sep 2;12:217. doi: 10.1186/s12967-014-0217-y.

3.

Discovery and Synthesis of C-Nucleosides as Potential New Anti-HCV Agents.

Draffan AG, Frey B, Pool B, Gannon C, Tyndall EM, Lilly M, Francom P, Hufton R, Halim R, Jahangiri S, Bond S, Nguyen VT, Jeynes TP, Wirth V, Luttick A, Tilmanis D, Thomas JD, Pryor M, Porter K, Morton CJ, Lin B, Duan J, Kukolj G, Simoneau B, McKercher G, Lagacé L, Amad M, Bethell RC, Tucker SP.

ACS Med Chem Lett. 2014 Apr 10;5(6):679-84. doi: 10.1021/ml500077j. eCollection 2014 Jun 12.

4.

Identification of benzofurano[3,2-d]pyrimidin-2-ones, a new series of HIV-1 nucleotide-competing reverse transcriptase inhibitors.

Tremblay M, Bethell RC, Cordingley MG, DeRoy P, Duan J, Duplessis M, Edwards PJ, Faucher AM, Halmos T, James CA, Kuhn C, Lacoste JÉ, Lamorte L, LaPlante SR, Malenfant E, Minville J, Morency L, Morin S, Rajotte D, Salois P, Simoneau B, Tremblay S, Sturino CF.

Bioorg Med Chem Lett. 2013 May 1;23(9):2775-80. doi: 10.1016/j.bmcl.2013.02.042. Epub 2013 Feb 16.

PMID:
23511023
5.

A simplified approach to predict CYP3A-mediated drug-drug interactions at early drug discovery: validation with clinical data.

Rioux N, Batonga J, Colombo F, Massé J, Zouki C, Ribadeneira MD, Duan J, Bethell RC.

Xenobiotica. 2013 Jul;43(7):592-7. doi: 10.3109/00498254.2012.751141. Epub 2012 Dec 17.

PMID:
23244592
6.

Evaluation of phosphatidylinositol-4-kinase IIIα as a hepatitis C virus drug target.

Vaillancourt FH, Brault M, Pilote L, Uyttersprot N, Gaillard ET, Stoltz JH, Knight BL, Pantages L, McFarland M, Breitfelder S, Chiu TT, Mahrouche L, Faucher AM, Cartier M, Cordingley MG, Bethell RC, Jiang H, White PW, Kukolj G.

J Virol. 2012 Nov;86(21):11595-607. doi: 10.1128/JVI.01320-12. Epub 2012 Aug 15.

7.

The liver partition coefficient-corrected inhibitory quotient and the pharmacokinetic-pharmacodynamic relationship of directly acting anti-hepatitis C virus agents in humans.

Duan J, Bolger G, Garneau M, Amad M, Batonga J, Montpetit H, Otis F, Jutras M, Lapeyre N, Rhéaume M, Kukolj G, White PW, Bethell RC, Cordingley MG.

Antimicrob Agents Chemother. 2012 Oct;56(10):5381-6. doi: 10.1128/AAC.01028-12. Epub 2012 Aug 6.

8.

Cross-species absorption, metabolism, distribution and pharmacokinetics of BI 201335, a potent HCV genotype 1 NS3/4A protease inhibitor.

Duan J, Yong CL, Garneau M, Amad M, Bolger G, De Marte J, Montpetit H, Otis F, Jutras M, Rhéaume M, White PW, Llinàs-Brunet M, Bethell RC, Cordingley MG.

Xenobiotica. 2012 Feb;42(2):164-72. doi: 10.3109/00498254.2011.611546. Epub 2011 Oct 11.

PMID:
21988548
9.

Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.

White PW, Llinàs-Brunet M, Amad M, Bethell RC, Bolger G, Cordingley MG, Duan J, Garneau M, Lagacé L, Thibeault D, Kukolj G.

Antimicrob Agents Chemother. 2010 Nov;54(11):4611-8. doi: 10.1128/AAC.00787-10. Epub 2010 Sep 7.

10.

Identification of a lipid kinase as a host factor involved in hepatitis C virus RNA replication.

Vaillancourt FH, Pilote L, Cartier M, Lippens J, Liuzzi M, Bethell RC, Cordingley MG, Kukolj G.

Virology. 2009 Apr 25;387(1):5-10. doi: 10.1016/j.virol.2009.02.039. Epub 2009 Mar 21.

11.

Apricitabine: a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor for the treatment of nucleoside-resistant HIV infection.

Wainberg MA, Cahn P, Bethell RC, Sawyer J, Cox S.

Antivir Chem Chemother. 2007;18(2):61-70. Review.

PMID:
17542150
12.

Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients.

Cahn P, Cassetti I, Wood R, Phanuphak P, Shiveley L, Bethell RC, Sawyer J.

AIDS. 2006 Jun 12;20(9):1261-8.

PMID:
16816554
13.

In vitro antiretroviral activity and in vitro toxicity profile of SPD754, a new deoxycytidine nucleoside reverse transcriptase inhibitor for treatment of human immunodeficiency virus infection.

Gu Z, Allard B, de Muys JM, Lippens J, Rando RF, Nguyen-Ba N, Ren C, McKenna P, Taylor DL, Bethell RC.

Antimicrob Agents Chemother. 2006 Feb;50(2):625-31.

14.
15.

Sialidase as a target for inhibitors of influenza virus replication.

Bethell RC, Smith PW.

Expert Opin Investig Drugs. 1997 Oct;6(10):1501-9.

PMID:
15989515
16.

Development of a 1-microl scale assay for mitogen-activated kinase kinase 7 using 2-D fluorescence intensity distribution analysis anisotropy.

Wright PA, Boyd HF, Bethell RC, Busch M, Gribbon P, Kraemer J, Lopez-Calle E, Mander TH, Winkler D, Benson N.

J Biomol Screen. 2002 Oct;7(5):419-28.

PMID:
14599357
17.

Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition.

Wang M, Ng KK, Cherney MM, Chan L, Yannopoulos CG, Bedard J, Morin N, Nguyen-Ba N, Alaoui-Ismaili MH, Bethell RC, James MN.

J Biol Chem. 2003 Mar 14;278(11):9489-95. Epub 2002 Dec 30.

18.

Development of a sensitive chemiluminescent neuraminidase assay for the determination of influenza virus susceptibility to zanamivir.

Buxton RC, Edwards B, Juo RR, Voyta JC, Tisdale M, Bethell RC.

Anal Biochem. 2000 May 1;280(2):291-300.

PMID:
10790313
19.

Virological Methods for the Generation and Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en.

McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, Jowett AJ, Bethell RC.

Methods Mol Med. 2000;24:375-82. doi: 10.1385/1-59259-245-7:375.

PMID:
21331924
20.

Biochemical Methods for the Characterization of Influenza Viruses with Reduced Sensitivity to 4-Guanidino-Neu5Ac2en.

Bethell RC, Hart GJ, Blick TJ, Sahasrabudhe A, McKimm-Breschkin JL.

Methods Mol Med. 2000;24:367-74. doi: 10.1385/1-59259-245-7:367.

PMID:
21331923
22.

Synthesis of a tetrasubstituted bicyclo [2.2.2] octane as a potential inhibitor of influenza virus sialidase.

Smith PW, Trivedi N, Howes PD, Sollis SL, Rahim G, Bethell RC, Lynn S.

Bioorg Med Chem Lett. 1999 Feb 22;9(4):611-4.

PMID:
10098674
23.

Synthesis of tetrasubstituted bicyclo[3.2.1]octenes as potential inhibitors of influenza virus sialidase.

Jones PS, Smith PW, Hardy GW, Howes PD, Upton RJ, Bethell RC.

Bioorg Med Chem Lett. 1999 Feb 22;9(4):605-10.

PMID:
10098673
24.

Sialidase inhibitors related to zanamivir: synthesis and biological evaluation of 4H-pyran 6-ether and ketone.

Smith PW, Robinson JE, Evans DN, Sollis SL, Howes PD, Trivedi N, Bethell RC.

Bioorg Med Chem Lett. 1999 Feb 22;9(4):601-4.

PMID:
10098672
25.
26.

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus.

Gubareva LV, Matrosovich MN, Brenner MK, Bethell RC, Webster RG.

J Infect Dis. 1998 Nov;178(5):1257-62.

PMID:
9780244
27.

Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors.

McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, McDonald M, Colman PM, Hart GJ, Bethell RC, Varghese JN.

J Virol. 1998 Mar;72(3):2456-62.

29.
30.

Plasmodium falciparum lacks sialidase and trans-sialidase activity.

Clough B, Atilola FA, Healy N, Pereira ME, Bethell RC, Penn CR, Pasvol G.

Parasitology. 1996 May;112 ( Pt 5):443-9.

PMID:
8677133
31.

Generation and characterization of variants of NWS/G70C influenza virus after in vitro passage in 4-amino-Neu5Ac2en and 4-guanidino-Neu5Ac2en.

McKimm-Breschkin JL, Blick TJ, Sahasrabudhe A, Tiong T, Marshall D, Hart GJ, Bethell RC, Penn CR.

Antimicrob Agents Chemother. 1996 Jan;40(1):40-6.

32.

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en.

Blick TJ, Tiong T, Sahasrabudhe A, Varghese JN, Colman PM, Hart GJ, Bethell RC, McKimm-Breschkin JL.

Virology. 1995 Dec 20;214(2):475-84.

35.

Benzophenone derivatives: a novel series of potent and selective inhibitors of human immunodeficiency virus type 1 reverse transcriptase.

Wyatt PG, Bethell RC, Cammack N, Charon D, Dodic N, Dumaitre B, Evans DN, Green DV, Hopewell PL, Humber DC, et al.

J Med Chem. 1995 May 12;38(10):1657-65.

PMID:
7538590
36.
37.

Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors: heterocyclic ring systems containing P1' and P2' substituents.

Kitchin J, Bethell RC, Cammack N, Dolan S, Evans DN, Holman S, Holmes DS, McMeekin P, Mo CL, Nieland N, et al.

J Med Chem. 1994 Oct 28;37(22):3707-16.

PMID:
7966131
38.

Synthesis and anti-HIV-1 activity of a series of imidazo[1,5-b]pyridazines.

Livermore DG, Bethell RC, Cammack N, Hancock AP, Hann MM, Green DV, Lamont RB, Noble SA, Orr DC, Payne JJ, et al.

J Med Chem. 1993 Nov 26;36(24):3784-94.

PMID:
7504733
39.

Synthesis and structure-activity relationships of a series of penicillin-derived HIV proteinase inhibitors containing a stereochemically unique peptide isostere.

Holmes DS, Bethell RC, Cammack N, Clemens IR, Kitchin J, McMeekin P, Mo CL, Orr DC, Patel B, Paternoster IL, et al.

J Med Chem. 1993 Oct 15;36(21):3129-36.

PMID:
8230099
40.

A series of penicillin derived C2-symmetric inhibitors of HIV-1 proteinase: synthesis, mode of interaction, and structure-activity relationships.

Humber DC, Bamford MJ, Bethell RC, Cammack N, Cobley K, Evans DN, Gray NM, Hann MM, Orr DC, Saunders J, et al.

J Med Chem. 1993 Oct 15;36(21):3120-8.

PMID:
8230098
41.

4-Guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro.

Woods JM, Bethell RC, Coates JA, Healy N, Hiscox SA, Pearson BA, Ryan DM, Ticehurst J, Tilling J, Walcott SM, et al.

Antimicrob Agents Chemother. 1993 Jul;37(7):1473-9.

42.

Supplemental Content

Loading ...
Support Center